EQS News: Half-year figures close with balanced EBITDA, Trauma with positive EBITDA | 14.08.24

• Revenue: H1/2024 up 10% to EUR 6.4 million compared to H1/2023; main growth driver EMEA region
• EBITDA: H1/2024 break-even, Trauma achieves positive EBITDA

monkey Implant AG (“monkey” or “Company”) looks back on a satisfactory first half year. The company was able to increase revenue and EBITDA compared to the previous year and to generate positive EBITDA in the trauma business. The company’s revenue increased by 10% to EUR 6.4 million compared to the same period of the previous year (H1/2023: EUR 5.9 million). In terms of profit, the company recorded an almost balanced EBITDA of EUR -0.0 million (H1/2023: EUR -1.0 million) in the first six months of 2024, which mainly reflects revenue growth combined with lower costs and restructuring effects.

H1/2024 – Key financial figures*

EBITDA H1/2024

monkey achieved a significantly improved EBITDA of EUR -0.0 million in the first half of 2024 compared to the same period of the previous year (H1/2023: EUR -1.0 million). The following developments were decisive for the result:

• Strong turnover growth (H1: +10% compared to last year),
• Stable high gross margin (> 87%),
• Decrease in personnel costs (-12%) in the first six months compared to the same period of the previous year,
• Improving margin and cost situation in the US

Cash flow

monkeyOperating cash flow improved by 34% year-on-year in the first half of 2024 to EUR 1.0 million at , mainly due to the improved operating result. Cash flow from investing activities showed an outflow of EUR 0.0 million in H1/2024, with investments in development projects accounting for EUR 22 thousand (H1/2023: EUR 59 thousand). In the area of ​​financing activities, there was a total cash inflow of EUR 0.5 million in the first half of 2024 (H1/2023: cash inflow of EUR 2.8 million), mainly due to the cash inflow from the capital increase of EUR 1.0 million net, the entering into of a shareholder loan of EUR 0.3 million, the repayment of financial liabilities and shareholder loans of EUR 0.6 million (H1/2023: EUR 0.5 million) and the payment of interest of EUR 133 thousand (H1/2023: EUR 80 thousand). As a result, cash and cash equivalents decreased to EUR 0.8 million at the end of the second quarter. Net debt (total cash and cash equivalents minus all interest-bearing liabilities) amounted to EUR 1.2 million as at 30 June 2024 (31 December 2023: EUR 1.8 million).

Prospect

Not included in the following forecast statements:

• A significant tightening of sanctions against Russia or a change in the interpretation of existing sanctions for other markets,
• An extension of the conflict situation outside Ukraine,
• Further significant additional increases in energy and commodity prices above currently foreseeable levels or restrictions on the Company’s ability to operate as a result of a partial or complete interruption of gas and/or energy supplies due to, among other things, the war in Ukraine,
• Financial risks resulting from recession-related measures in various markets and their impact on government finances in the healthcare sector.

In the second half of 2024 the focus will be on stabilization monkey’the Company’s financial position to fund the next phase of its antibacterial implant technology activities, complete patient recruitment for the human clinical trial for the innovative antibacterial implant technology, initiate approval documentation and submit applications for the EIC program and the upcoming MDR audit.

In terms of turnover, the Board of Directors expects turnover for the second half of 2024 to remain in line with the first six months and expects to achieve the planned turnover level of between EUR 11.5 million and EUR 13.5 million for the financial year 2024. Taking into account the full project costs for the further execution of the human clinical trial for the antibacterial implant technology, the Board of Directors expects EBITDA for the financial year 2024 to be between EUR -2.5 million and -1.4 million.

——————————————– —- ———-

monkey Implantate AG (ISIN DE0005066609) – General Standard/Regulated Market – All German stock exchanges –

About monkey Implant AG

monkey Implantate AG is a globally active medical technology company based in Berlin, Germany. The company develops, manufactures and markets products for traumatology. The IP-protected portfolio includes the innovative anatomical plating system LOQTEQ® and a wide range of cannulated screws. In addition monkey Implantate AG has an innovation pipeline with promising development projects such as antibacterial silver coating technology and magnesium-based implants. These technologies address critical problems in traumatology that have not yet been adequately solved. In Germany, monkey Implantate AG sells its products directly to hospitals, purchasing groups and group clinics, while internationally it primarily uses a broad network of distributors in approximately 25 countries. In the US, the company relies on A hybrid sales strategy through its subsidiary monkey Implants Inc. Sales are through distribution agents and through partnerships with global orthopedic companies. The monkey The Implantate AG share is listed in the General Standard of the Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit our website www.aap.de.

There may be technical rounding differences in the figures presented in this press release, which do not affect the overall statement. All key financial figures relating to the balance sheet date of December 31, 2023 in the published consolidated interim report as of June 30, 2024 are provisional and unaudited. The 2023 operating figures will be confirmed at a later date with the publication of the 2023 annual accounts.

Forward-looking statements

This press release may contain forward-looking statements based on the current expectations, assumptions and forecasts of the Board of Management and information currently available to it. Forward-looking statements should not be interpreted as guarantees of future developments and results mentioned therein. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual results, financial situation, development or performance of the company and the estimates given here. These factors include factors that monkey has described in published reports. Forward-looking statements therefore speak only as of the date on which they are made. We assume no obligation to update the forward-looking statements in this press release or to adapt them to future events or developments.

If you have any questions, please contact: monkey Implantate AG; Rubino Di Girolamo, Chairman of the Board of Management/CEO, Lorenzweg 5; 12099 Berlin

Phone: +49 (0)30 75019 – 170; Fax: +49 (0)30 75019 – 290; E-mail: [email protected]

Contact:
Contact:
aap Implantate AG; Fabian Franke; Investor Relations; Lorenzweg 5; D-12099 Berlin Tel.: ++49/30/750 19 – 134; Fax.: ++49/30/750 19 – 290; [email protected]